Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study

Qiang Shen, Fang Du, Shiliang Huang, Pavel Rodriguez, Lora Talley Watts, Timothy Q. Duong

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. This study evaluated the efficacy of MB to treat ischemic stroke in rats using longitudinal MRI and behavioral measures. Rats were subjected to 60-minute middle-cerebral-artery occlusion. In a randomized double-blinded design, vehicle or MB was administered after reperfusion. The initial lesion volumes at 30 minutes post-ischemia were not significantly different between the two groups (P = 0.92). The final infarct volumes two days after stroke increased in the vehicle group but decreased in the MB group, yielding a 30% difference in infarct volume (P = 0.03). Tracking tissue fate on a pixel-by-pixel basis showed that MB salvaged more initial core pixels compared to controls (22±3% versus 11±3%, P = 0.03), and more mismatch pixels compared to controls (83±3% versus 61±8%, P = 0.02). This study demonstrates MB treatment minimizes ischemic brain injury and improves functional outcomes.

Original languageEnglish (US)
Article numbere79833
JournalPLoS One
Volume8
Issue number11
DOIs
StatePublished - Nov 21 2013

Fingerprint

methylene blue
Methylene Blue
stroke
Magnetic resonance imaging
Stroke
Pixels
infarction
Rats
methemoglobinemia
Methemoglobinemia
Middle Cerebral Artery Infarction
rats
Cyanides
cyanides
ischemia
lesions (animal)
Poisoning
Brain Injuries
arteries
Reperfusion

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Shen, Q., Du, F., Huang, S., Rodriguez, P., Watts, L. T., & Duong, T. Q. (2013). Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study. PLoS One, 8(11), [e79833]. https://doi.org/10.1371/journal.pone.0079833

Neuroprotective efficacy of methylene blue in ischemic stroke : An MRI study. / Shen, Qiang; Du, Fang; Huang, Shiliang; Rodriguez, Pavel; Watts, Lora Talley; Duong, Timothy Q.

In: PLoS One, Vol. 8, No. 11, e79833, 21.11.2013.

Research output: Contribution to journalArticle

Shen, Q, Du, F, Huang, S, Rodriguez, P, Watts, LT & Duong, TQ 2013, 'Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study', PLoS One, vol. 8, no. 11, e79833. https://doi.org/10.1371/journal.pone.0079833
Shen Q, Du F, Huang S, Rodriguez P, Watts LT, Duong TQ. Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study. PLoS One. 2013 Nov 21;8(11). e79833. https://doi.org/10.1371/journal.pone.0079833
Shen, Qiang ; Du, Fang ; Huang, Shiliang ; Rodriguez, Pavel ; Watts, Lora Talley ; Duong, Timothy Q. / Neuroprotective efficacy of methylene blue in ischemic stroke : An MRI study. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{06d2d6d6d9be4782821f1f74f0a3c0fe,
title = "Neuroprotective efficacy of methylene blue in ischemic stroke: An MRI study",
abstract = "Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. This study evaluated the efficacy of MB to treat ischemic stroke in rats using longitudinal MRI and behavioral measures. Rats were subjected to 60-minute middle-cerebral-artery occlusion. In a randomized double-blinded design, vehicle or MB was administered after reperfusion. The initial lesion volumes at 30 minutes post-ischemia were not significantly different between the two groups (P = 0.92). The final infarct volumes two days after stroke increased in the vehicle group but decreased in the MB group, yielding a 30{\%} difference in infarct volume (P = 0.03). Tracking tissue fate on a pixel-by-pixel basis showed that MB salvaged more initial core pixels compared to controls (22±3{\%} versus 11±3{\%}, P = 0.03), and more mismatch pixels compared to controls (83±3{\%} versus 61±8{\%}, P = 0.02). This study demonstrates MB treatment minimizes ischemic brain injury and improves functional outcomes.",
author = "Qiang Shen and Fang Du and Shiliang Huang and Pavel Rodriguez and Watts, {Lora Talley} and Duong, {Timothy Q.}",
year = "2013",
month = "11",
day = "21",
doi = "10.1371/journal.pone.0079833",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Neuroprotective efficacy of methylene blue in ischemic stroke

T2 - An MRI study

AU - Shen, Qiang

AU - Du, Fang

AU - Huang, Shiliang

AU - Rodriguez, Pavel

AU - Watts, Lora Talley

AU - Duong, Timothy Q.

PY - 2013/11/21

Y1 - 2013/11/21

N2 - Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. This study evaluated the efficacy of MB to treat ischemic stroke in rats using longitudinal MRI and behavioral measures. Rats were subjected to 60-minute middle-cerebral-artery occlusion. In a randomized double-blinded design, vehicle or MB was administered after reperfusion. The initial lesion volumes at 30 minutes post-ischemia were not significantly different between the two groups (P = 0.92). The final infarct volumes two days after stroke increased in the vehicle group but decreased in the MB group, yielding a 30% difference in infarct volume (P = 0.03). Tracking tissue fate on a pixel-by-pixel basis showed that MB salvaged more initial core pixels compared to controls (22±3% versus 11±3%, P = 0.03), and more mismatch pixels compared to controls (83±3% versus 61±8%, P = 0.02). This study demonstrates MB treatment minimizes ischemic brain injury and improves functional outcomes.

AB - Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. This study evaluated the efficacy of MB to treat ischemic stroke in rats using longitudinal MRI and behavioral measures. Rats were subjected to 60-minute middle-cerebral-artery occlusion. In a randomized double-blinded design, vehicle or MB was administered after reperfusion. The initial lesion volumes at 30 minutes post-ischemia were not significantly different between the two groups (P = 0.92). The final infarct volumes two days after stroke increased in the vehicle group but decreased in the MB group, yielding a 30% difference in infarct volume (P = 0.03). Tracking tissue fate on a pixel-by-pixel basis showed that MB salvaged more initial core pixels compared to controls (22±3% versus 11±3%, P = 0.03), and more mismatch pixels compared to controls (83±3% versus 61±8%, P = 0.02). This study demonstrates MB treatment minimizes ischemic brain injury and improves functional outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84894344975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894344975&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079833

DO - 10.1371/journal.pone.0079833

M3 - Article

C2 - 24278191

AN - SCOPUS:84894344975

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79833

ER -